Management of HIV Treatment Failure
For confirmed virologic failure (HIV-1 RNA >200 copies/mL on two consecutive tests) with good adherence, immediately order genotype resistance testing and resume the current dolutegravir- or bictegravir-based regimen while awaiting results—do not wait for resistance testing to restart therapy. 1
Initial Assessment and Immediate Action
When virologic failure is confirmed, the priority is to:
- Order genotype resistance testing immediately to guide subsequent therapy decisions
- Resume the most recent dolutegravir- or bictegravir-based regimen even before resistance results return, provided adherence is confirmed good and the patient is willing 1
This approach is supported by prospective data showing high rates of virologic suppression when patients resume high-barrier regimens with improved adherence 1. Due to the high resistance barrier of contemporary integrase inhibitor-based regimens, many individuals will have no detectable drug resistance 1.
Selecting New Therapy Based on Resistance Results
If No or Limited Resistance Detected:
- Switch to dolutegravir plus tenofovir/emtricitabine (or lamivudine) 1
- This approach provides comparable or superior virologic suppression rates even in the presence of NRTI resistance 1
- Monitor more closely in the first year if NRTI resistance is present, especially if adherence concerns exist 1
If Multiclass Resistance Including InSTI Resistance:
Use novel mechanism agents: ibalizumab, fostemsavir, or lenacapavir—ideally combining two fully active drugs 1
Key considerations:
- Continue NRTIs (tenofovir/emtricitabine or lamivudine) as they retain partial activity even with extensive resistance mutations 1
- This scenario is uncommon and typically reflects years of nonsuppressive regimens or long periods of intermittent adherence 1
Special Circumstances
For Patients Unable to Take Oral ART Consistently:
Long-acting cabotegravir plus long-acting rilpivirine may be considered only if ALL of the following criteria are met 1:
- Unable to take oral ART consistently despite extensive efforts and clinical support
- High risk of HIV disease progression (CD4+ count <200/μL or history of AIDS-defining complications)
- Virus susceptible to both cabotegravir and rilpivirine
- Intensive case management and adherence support are available
This is NOT recommended if there is documented or suspected resistance to either agent 1
Critical Pitfalls to Avoid
Do not change therapy for "blips" (HIV RNA 20-200 copies/mL intermittently) or persistent low-level viremia at this range 1. These patients are unlikely to benefit from ART intensification 1
Do not switch from boosted protease inhibitors to NNRTI or first-generation InSTI regimens (raltegravir or elvitegravir) if previous NRTI resistance exists 1
Do not delay restarting therapy while waiting for resistance results if the patient was on a high-barrier regimen (dolutegravir or bictegravir-based) 1
Always evaluate for drug interactions, particularly multivalent cations (calcium, magnesium, iron, zinc) that impair InSTI absorption 1
Evidence Quality Note
The 2025 IAS-USA guidelines 1 represent the most current and authoritative recommendations, with evidence ratings of AIa (strongest) for most recommendations regarding virologic failure management. Recent real-world data from 2026 2 confirms that virologic failure rates have declined over time (from 4.7% to 1.7%) with modern regimens, and INSTI-based switches consistently achieve resuppression without promoting multiclass resistance.